share_log

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $2

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $2

Ascendiant Capital维持对Outlook Therapeutics的买入,将目标股价
Benzinga ·  2023/12/29 06:47

Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $1.5 to $2.

Ascendiant Capital分析师爱德华·胡维持Outlook Therapeutics(纳斯达克股票代码:OTLK)的买入并将目标股价从1.5美元上调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发